Study identifier:TC-1734-226-CRD-005
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)
ADHD
Phase 2
No
Placebo, AZD3480
All
45
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
Targacept Inc.
No locations available
Arms | Assigned Interventions |
---|---|
Placebo Comparator: 1 | Drug: Placebo Placebo |
Experimental: 2 | Drug: AZD3480 Capsules 5 mg/day (once a day) for 2 weeks Other Name: AZD3480 |
Experimental: 3 | Drug: AZD3480 Capsules 50 mg/day (once a day) for 2 weeks Other Name: AZD3480 |